Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...

Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...